^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    autologous TriCAR T

    i
    Other names: autologous TriCAR T, CD19/CD20/CD22 CAR-T
    Associations

    News

    Trials
    Company:
    Baylor College of Medicine
    Drug class:
    CD19-targeted CAR-T immunotherapy, CD20-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    almost2years
    CAR-T Cell, B-cell Acute Lymphoblastic Leukemia (TriCAR) (clinicaltrials.gov)
    P1, N=38, Not yet recruiting, Baylor College of Medicine | Trial primary completion date: Mar 2025 --> Mar 2026
    Trial primary completion date • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD19 expression
    |
    cyclophosphamide • fludarabine IV • autologous TriCAR T